LLYBy Calypso Research8 min read

Eli Lilly and Company (LLY) Q4 2025 Earnings Analysis

The Obesity Battle Ramps Up with $19.3B Boost

Key Takeaways

Eli Lilly and Company (LLY) reported Q4 2025 earnings with revenue of $19.3B, representing a +42.6% year-over-year change. The stock moved +10.3% on earnings day.

The bull case: Lilly’s dominant incretin portfolio, rapid expansion of access (Medicare, employers, global), and emerging multi-indication obesity and immunology strategies support sustained high growth and a durable, consumer-like platform with significant pricing and data advantages.

The bear case: Intensifying pricing pressure, heavy reliance on obesity cash-pay dynamics, uncertain oral–injectable cannibalization, and execution risk in diversifying into other therapeutic areas could limit upside to long-term growth and margin expectations.

Financial Highlights

  • Revenue: $19.3B (+42.6% YoY)
  • Gross Profit: $16.4B (85.1% margin, +2.8% YoY)
  • Operating Income: $8.8B (45.5% margin, +2.6% YoY)
  • Net Income: $6.6B
  • TTM Revenue: $65.2B

Stock Performance

  • Earnings Day Move: +10.3%
  • Year-to-Date: -2.0%
  • 1-Year Return: +20.1%
  • vs. S&P 500 (since earnings): +15.7%
  • vs. Nasdaq (since earnings): +19.1%

View live LLY data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Eli Lilly and Company's Q4 2025 earnings call:

How Big and How Fast? Medicare, Employer, and Cash‑Pay Dynamics in Obesity (Zepbound / Mounjaro / Lilly Direct)

Sentiment: Positive

"As highlighted in the call text, basically, we are expecting that access to be granted no later than July 1... there is a bolus of patients that we have nowadays in the Lilly Direct business that we believe are also Medicare patients... expect that bolus, I think, is between 10-20% will actually move into the Medicare space." — Lucas Montarce
"Obviously, we start the year roughly on balance, stable... putting additional focus in the employer space... The initial conversations and feedback have been positive... We anticipate having some of those decisions and increased coverage over time in the employer space as we head into the back end of this year and mostly into 2027." — Ilya Yuffa

Orforglipron: Launch Trajectory, Cannibalization Risk, and Market Expansion vs. Substitution

Sentiment: Positive

"First of which is just market expansion... we're very encouraged by what we're seeing with oral Wegovy as it validates our belief that there's a substantial number of people with overweight and obesity who have been sitting on the sidelines waiting for an oral option... We think this is going to be about patient satisfaction... our profile, which is simple with no restrictions on food and water intake, could make a big difference in the real world." — Kenneth Custer
"Looking at even just the last four weeks of the data of the competitor launch, is mainly expansion of the market. So we are very, very encouraged from, again, the first month of seeing that data and it's very much consistent with our expectations and our guide." — Lucas Montarce

U.S. and Global Pricing Pressure vs. Volume Growth: Sustainability of the Incretin Profit Engine

Sentiment: Positive

"Price is expected to be a drag on growth in the low to mid-teens... Three factors will impact US price: the government access agreement for obesity medicines, updated direct-to-patient Zepbound pricing, and lower Medicaid prices for later life cycle medicines." — Lucas Montarce
"From a pricing standpoint, we've been pretty transparent on pricing for 2026 as it relates to Part D, as well as our direct-to-patient pricing, which we implemented in December... we've seen an increase in utilization of even Zepbound vial at the end of the year when we implemented improved entry price of $2.99 for Zepbound." — Ilya Yuffa

Long-Term Shape of the Obesity Franchise: Indications Beyond Weight and the Value of Comorbidity Labels

Sentiment: Positive

"Even with Zepbound and looking at the Medicare population around sleep apnea, we're seeing an increase in utilization and thinking about obesity beyond weight and looking at outcomes related to obesity... we do see a growing body of evidence to support covering obesity medications for the population and having a positive impact on public health beyond just weight." — Ilya Yuffa
"As our incretin portfolio and amylin portfolio expands, we're always facing the question of do we spend our resources replicating findings from previous incretins on comorbidities and complications where we know these drugs are efficacious, or do we push into new areas and generate new evidence?... we're actually starting to explore new ideas like stress urinary incontinence, peripheral artery disease, and hypertension." — Kenneth Custer

Consumerization of Lilly: Is This Now a “Consumer Stock” and What Are the Right Analogs?

Sentiment: Positive

"I am hard-pressed to think of an analog where you have this many people paying out of pocket for prescription medication... you can look at cosmetics and aesthetics... but that also has some overlap but not complete because here you have really profound health benefits and noticeable results that really drives a success cycle for people in their lives." — David Ricks
"What we can do is take learnings from other industries that were able to reduce consumer friction, unlock the power of first-party data in marketing... consider, you know, a platform and an interface with consumers that allows us to bring our really robust and deep pipeline... to market in a way that might be quite differentiated over time. Play with pricing opportunities, subscription models, these kinds of things." — David Ricks

Bull Case

Lilly’s dominant incretin portfolio, rapid expansion of access (Medicare, employers, global), and emerging multi-indication obesity and immunology strategies support sustained high growth and a durable, consumer-like platform with significant pricing and data advantages.

Bear Case

Intensifying pricing pressure, heavy reliance on obesity cash-pay dynamics, uncertain oral–injectable cannibalization, and execution risk in diversifying into other therapeutic areas could limit upside to long-term growth and margin expectations.

Looking Ahead

With revenue growing +42.6% year-over-year, the key question is whether Eli Lilly and Company can sustain this growth trajectory, particularly around how Big and How Fast? Medicare, Employer, and Cash‑Pay Dynamics in Obesity (Zepbound / Mounjaro / Lilly Direct). With operating margins at 45.5%, margin trends will remain a focal point. The market's positive reaction on earnings day suggests confidence in management's direction, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Eli Lilly and Company's revenue in Q4 2025?

Eli Lilly and Company reported Q4 2025 revenue of $19.3B, representing a +42.6% year-over-year change.

Did Eli Lilly and Company beat earnings expectations in Q4 2025?

The stock rose +10.3% on earnings day, suggesting the results met or exceeded market expectations. The current bull case centers on: Lilly’s dominant incretin portfolio, rapid expansion of access (Medicare, employers, global), and emerging multi-indication obesity and immunology strategies support sustained high growth and a durable, consumer-like platform with significant pricing and data advantages.

What is the bull case for LLY stock?

The bull case for LLY centers on: Lilly’s dominant incretin portfolio, rapid expansion of access (Medicare, employers, global), and emerging multi-indication obesity and immunology strategies support sustained high growth and a durable, consumer-like platform with significant pricing and data advantages.

What is the bear case for LLY stock?

The bear case for LLY centers on: Intensifying pricing pressure, heavy reliance on obesity cash-pay dynamics, uncertain oral–injectable cannibalization, and execution risk in diversifying into other therapeutic areas could limit upside to long-term growth and margin expectations.

How has LLY stock performed since its Q4 2025 earnings?

LLY moved +10.3% on the day of its Q4 2025 earnings report, outperforming the S&P 500 by +15.7% since earnings. Year-to-date, the stock has returned -2.0%.

Browse all 400+ earnings reports →

Learn More

Analyze LLY in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Eli Lilly and Company and 400+ other stocks, explore the full platform.

Open LLY on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.